

Satellite Symposium

Dual Elimination of Maternal-to-Child Transmission of HIV and Syphilis

The Time is Now



Welcome and Overview

Sanjana Bhardwaj
HIV and Nutrition
UNICEF

Global problem of maternal HIV and syphilis – why is that important?

Professor Helen Rees
Reproductive Health Research Unit
University of Witwatersrand

Dual Elimination: Efforts to eliminate maternal-to-child transmission of HIV and syphilis and the use of and performance of rapid dual HIV and syphilis tests

Professor Jeffrey D. Klausner
Global Health and Infectious Diseases
University of California Los Angeles

Dual Elimination: Efforts to eliminate maternal-to-child transmission of HIV and syphilis and the use of and performance of rapid dual HIV and syphilis tests

Jeffrey D. Klausner, MD, MPH

Professor of Medicine and Public Health
Attending Physician Ronald Reagan Medical Center


Division of Infectious Diseases and Program in Global Health
David Geffen School of Medicine

Department of Epidemiology
Karin and Jonathan Fielding School of Public Health

December 8, 2013
Cape Town

Disclosures

- In the past 12 months, Dr. Klausner has received research funding, supplies or unrestricted educational gifts from:
 - US NIH
 - US CDC
 - Hologic Gen-Probe, Inc.
 - Cepheid, Inc.
 - Standard Diagnostics, Inc.
 - APLA Health and Wellness
 - Qpid.me

A handwritten signature in black ink on a white rectangular background. The signature appears to read "Jeffrey A. Klausner" in a cursive script.

JDKlausner@mednet.ucla.edu

Outline

1. WHO efforts to eliminate mother-to-child transmission of syphilis
2. UNAIDS efforts to eliminate mother-to-child transmission of HIV infection
3. Dual elimination
4. New dual rapid tests

What is elimination?

- Elimination of disease is the reduction in disease incidence below a threshold of public health importance in a geographic area
 - Perinatal HIV infection: < 90% reduction from 2011, < 50 per 100,000 live births
 - Congenital syphilis: < 50 per 100,000 live births
- Eradication of disease is the abrogation of disease from planet Earth, e.g., small pox

What is congenital syphilis?

- Miscarriage
- Prematurity
- Stillbirth
- Low birth weight
- Neonatal death
- Clinical syphilis in neonate



From Zhou, STD, 2007

Global Surveillance Case Definition for Congenital Syphilis

- A stillbirth, live birth, or fetal loss at >20 weeks gestation or >500g in a syphilis-seropositive mother without adequate* syphilis treatment


OR

- A stillbirth, live birth, or child aged <2 years with microbiological evidence of syphilis infection

*Adequate treatment defined in syphilis-positive mothers receiving at least 1 dose of benzathine penicillin G before 24 weeks gestation

WHO Global Elimination of Congenital Syphilis Initiative, 2007

- **Objective**
 - To eliminate congenital syphilis as a public health problem
- **Aim**
 - Prevent transmission of syphilis from mother to child
- **Targets by 2015**
 - Screen > 95% of first antenatal care attendees for syphilis
 - Treat > 95% of syphilis-seropositive antenatal care attendees



Rationale

- Almost all nations have national policies recommending universal syphilis screening for pregnant women
- Current technology allows testing even in settings that lack basic laboratory capacity
- Maternal syphilis testing/treatment is highly cost effective
 - <\$1 per woman tested and treated
 - \$200 per case averted
 - \$15 per DALY saved



Prevention of congenital syphilis is highly feasible and cost-effective

- Simple and accurate tests
 - Rapid point-of-care tests, no laboratory
 - Sensitivity > 95%
- Penicillin treatment
 - Widely available
 - One dose of penicillin early in pregnancy is highly-effective
 - Penicillin in pregnancy is safe
- Screening all pregnant women is cost-effective even in low prevalence settings



Elimination of congenital syphilis helps reach global goals

Millennium Development Goals 4-6

- 4: Prevention of congenital syphilis reduces neonatal mortality
- 5: Early antenatal care and fewer spontaneous abortions and stillbirths improve maternal health
- 6: Women with syphilis are at greater risk of acquiring and transmitting HIV



UN Secretary General's Global Strategy for Women's and Children's Health

Ensure universal access for women and children to a comprehensive, integrated package of essential interventions & services




Congenital syphilis is common and severe


WHO estimates, 2008

- About 1.4 million pregnant women infected with syphilis per year
 - Majority of infected women unidentified, untreated, or treated late in pregnancy
 - **Over 500,000** infected pregnant women will have an adverse outcome of pregnancy attributable to syphilis (congenital syphilis)
 - 215,000 stillbirths / early fetal losses
 - 90,000 neonatal deaths
 - 65,000 preterm or low birth-weight infants
 - 150,000 infants with congenital disease
- } Congenital syphilis is an important cause of neonatal mortality and morbidity

Percent pregnant women syphilis seropositive, 2008



Reported syphilis prevalence for 2010 (2009 for Indonesia) in intensified support countries for the investment case for eliminating mother-to-child transmission of syphilis^a



^a Source: Data for Papua New Guinea are from the National Department of Health, STI, HIV and AIDS Surveillance Unit: The 2010 STI, HIV and AIDS Annual Surveillance Report. Data for Indonesia available at: <http://www.who.int/hiv/pub/2010progressreport/en/index.html>. Data for all other countries available at: http://www.who.int/hiv/pub/progress_report2011/en/.

The Four Pillars of Elimination of Congenital Syphilis

I. Ensure sustained political commitment and **advocacy**

II. Increase access to, and quality of, maternal and newborn health **services**


III. **Screen** all pregnant women and **treat** all positives

IV. Conduct surveillance, **monitoring** and **evaluation**


Outline

1. WHO efforts to eliminate mother-to-child transmission of syphilis
2. UNAIDS efforts to eliminate mother-to-child transmission of HIV infection
3. Dual elimination
4. New dual rapid tests

PMTCT HIV: The Global Plan



Number of new HIV infections among children, 2009



1.4 million HIV-infected pregnant women
~ 235,000 HIV-infected babies

The Four Prongs of PMTCT HIV Infection

I. Prevent new HIV infections in women of reproductive age

II. Reduce unintended pregnancy in HIV-infected women

III. Prevent mother-to-child HIV transmission

IV. Provide care, treatment and support for HIV-infected women and children


Congenital Syphilis is More Common
than Perinatal HIV Infection

True or False?

Congenital Syphilis is More Common than Perinatal HIV Infection Worldwide

- About same number pregnant women each year have HIV or syphilis
 - Most (80%) untreated maternal syphilis infections result in serious pregnancy complications—miscarriages, preterm deliveries and stillbirth
 - **500,000 adverse birth outcomes each year** each year are caused by inadequately treated maternal syphilis; many fetal losses (miscarriages) and stillbirths go unrecognized
 - Roughly 53% receive ART reducing transmission to < 5% (37,000 HIV+ infants)
 - Remaining 47% untreated transmit in 30% (197,400 HIV+ infants)
 - **About 234,400 HIV-infected newborns** each year

Number of estimated newborn HIV and congenital syphilis cases by country, 2008



Outline

1. WHO efforts to eliminate mother-to-child transmission of syphilis
2. UNAIDS efforts to eliminate mother-to-child transmission of HIV infection
3. Dual elimination
4. New dual rapid tests

Preventing MTCT of HIV and syphilis: Why do this together?

- Both are sexually transmitted infections that cause substantial global health burden to mothers and infants
- Both have evidence-based, scalable interventions using antenatal care platform
 - Early access to antenatal care, testing and treatment
 - Both require engaging partners
- Both have affordable, accurate point-of-care tests feasible for use in basic settings
 - Prompt test results & treatment
 - ideally “**STAT**” (Same-visit Testing and Treatment)
 - Testing at all antenatal care facilities - not just those clinics with lab capacity
- Comprehensive services may be more attractive to women
 - Preliminary evidence from Zambia & Uganda suggested positive impact on HIV testing, ARV, and referral when both tests provided

Globally important

- *“In Zambia, if we’re going to be successful in eliminating pediatric AIDS, we also have to prevent congenital syphilis...It is simply unacceptable for this disease to continue to plague women and children.”*
Susan Strasser, Zambia Director,
Elizabeth Glaser Pediatric AIDS
Foundation

Accelerating Introduction of dual syphilis & HIV rapid diagnostic tests

A simple, proven, and inexpensive dual test for syphilis and HIV, combined with a web-linked hand-held optical reading device, could improve the quality, acceptability, and uptake of testing and treatment in rural areas to accelerate elimination of MTCT of syphilis and HIV.

Why do we care?

- Globally, syphilis caused 200,000 stillbirths and neonatal deaths in 2010, and 200,000 children were newly infected with HIV in 2010.
- There are 100 million people in rural areas in Zambia who are at greatest risk.
- 1.5% of pregnant women are seropositive for syphilis.
- 1.2% of pregnant women are seropositive for HIV.
- Syphilis infection program remains the most underfunded in the country for HIV.
- The lack of opportunity to make a difference in Zambia.
- Why do pregnant women who remain in the long-term prevention care network care?
- Seropositive status does not translate to access that all pregnant women are tested for syphilis and HIV in early pregnancy.

What will we do?

- Assess laboratory performance of newly available dual rapid diagnostic tests (RDT) for syphilis & HIV.
- Field test the highest performing RDT along with a web-linked hand-held optical reader offering point-of-care care algorithms.

What will we learn?

- Dual RDT performance.
- Acceptability of dual testing patients and staff.
- Effect of optical reader on improving testing quality and data management.
- Feasibility of web-based surveillance to improve program and procurement.
- Acceptability of patient education algorithms.
- Changes in utilization of health services.

What difference will this innovation make?

- We can help eliminate mother-to-child transmission of syphilis and HIV in 100,000 children born in Zambia each year.
- Improved data can provide evidence for informed public health decision-making.
- Current protocol can be used for other infections associated with up-impacted maternal services.

For more information: Dr. Lee Brown, lee@ghis.org

www.unhcr.org/refugees/information/people-and-their-problems

Maternal syphilis increases HIV transmission

- Of 1147 HIV-infected pregnant women, 92 (8.0%) syphilis
- Maternal syphilis was associated with increased in utero HIV transmission
aRR = 2.77; 1.40-5.46,
- Maternal syphilis was associated with increased intra/post-partum HIV transmission
aRR = 2.74; 1.58-4.74,

Adjusted for recent fever, breast infection, low birth weight and maternal HIV-1 viral load.

Characteristic	<i>In utero</i> HIV-1 MTCT [ARR (95% CI)]	P	Intrapartum/postnatal HIV-1 MTCT [ARR (95% CI)]	P
Syphilis infection				
No	Reference		Reference	
Yes	2.77 (1.40–5.46)	0.003	2.74 (1.58–4.74)	0.0003
Log ₁₀ HIV viral load				
< 3.993	Reference		Reference	
3.993 to < 4.547	1.98 (0.63–6.29)	0.24	1.54 (0.64–3.69)	0.34
4.557 to < 5.036	2.77 (0.91–8.40)	0.07	2.41 (1.07–5.43)	0.03
> 5.036	3.80 (1.31–11.02)	0.01	2.62 (1.16–5.90)	0.02
Low birth weight				
No	Reference		Reference	
Yes	1.52 (0.82–2.79)	0.18	1.88 (1.17–3.05)	0.01
Recent fever ^a				
No	NI		Reference	
Yes	NI		1.73 (1.09–2.74)	0.02
Breast infection				
No	NA	NA	Reference	
Yes	NA	NA	2.09 (1.06–4.12)	0.03

^aIncludes women with fever 1 week prior to enrolment and those with temperature > 37.5°C at enrolment. ARR, Adjusted relative risk; CI, confidence interval; NI, variable not included in the multivariate model; NA, since breast infection was determined at least 6 weeks postnatally, this variable was not assessed as a predictor of *in utero* HIV-1 MTCT.

Maternal syphilis infection is associated with increased risk of mother-to-child transmission of HIV in Malawi.

Mwapasa, Victor; Rogerson, Stephen; Kwiek, Jesse; Wilson, Paul; Milner, Danny; Molyneux, Malcolm; Kamwendo, Deborah; Tadesse, Eyob; Chaluluka, Ebbie; Meshnick, Steven. AIDS. 2006. 20(14):1869-1877.

WHO Dual Elimination Strategy

The sound of silence: missing the opportunity to save lives at birth

Jeffrey D Klausner*

The adverse impact of syphilis on child health has been known for over 500 years, yet the World Health Organization (WHO) only targeted congenital syphilis for elimination in 2007.¹ Syphilis in pregnancy is not rare. For more pregnant women have syphilis than human immunodeficiency virus (HIV) infection: 1.9 million (2008) and 1.49 million (2010), respectively.² The fraction of pregnant women with syphilis that is detected and treated is unknown, but estimates suggest that it is less than 10%.³ Whereas untreated maternal HIV infection is transmitted to infants in about one third of the cases, untreated maternal syphilis nearly always results in an adverse pregnancy outcome. For these reasons, syphilis is as important an infection during pregnancy as infection with the HIV, it therefore makes sense to build on global efforts to prevent and treat HIV infection during pregnancy to strengthen the fight against maternal syphilis.

The adverse pregnancy outcomes that can result from syphilis include fetal death, stillbirth or premature birth, low birth weight and congenital syphilis infection. The frequency of these outcomes has been poorly quantified. In a literature review published in the present issue of the Bulletin, Gomez et al. tried to generate summary estimates of syphilis-related adverse pregnancy outcomes by reviewing 3258 studies published through December 2011. They specifically looked for studies that compared pregnancy outcomes in untreated syphilitic women and non-syphilitic women belonging to the general population. Only 6 studies, representing 1715 pregnant women with untreated syphilis and 22 343 non-syphilitic women, satisfied these criteria and were included in the analysis. Adverse birth outcomes were observed in 46.5% (range: 33.4–61.8) of the women with untreated syphilis and in 14.3% (range: 10.25–20.8) of the women without syphilis. Hence, the frequency of adverse pregnancy outcomes was 4.5 times higher in the former than in the latter group.

The adverse pregnancy outcomes associated with maternal syphilis can be easily prevented, yet implementing proper measures within health systems has been difficult.⁴ Laboratory-based and rapid point-of-care syphilis tests identify most maternal syphilis infections. A single dose of benzathine penicillin early in pregnancy is highly effective at preventing adverse pregnancy outcomes.⁵ Testing and treatment combined cost less than one United States dollar. The problem, then, is not a lack of affordable tests or treatment, but the absence of political will. In many countries, most maternal syphilis infections remain undiagnosed and untreated. Currently 12 countries – the Central African Republic, China, Ghana, Honduras, Indonesia, Madagascar, Mozambique, Myanmar, Papua New Guinea, the United Republic of Tanzania, Uganda and Zambia – are recognized by WHO as high priority countries for congenital syphilis elimination owing to their large burden of maternal syphilis.⁶ Additionally, countries such as Bangladesh, Brazil and Nigeria have large populations and high rates of maternal syphilis and should be considered priority countries as well.

No one knows why some global disease elimination programmes have traction while others, such as the one for congenital syphilis, do not. Shiffman & Smith articulated a four-category framework for the prioritization of global health initiatives: actor power (or leadership), ideas (or communication), political context and factors such as disease severity, availability of effective interventions and existence of credible indicators.⁷ Since these are all well established in the case of congenital syphilis, the lack of traction must have to do with leadership, communication and politics. Aware that progress on congenital syphilis elimination has been slow, in June 2012 WHO updated its elimination strategy to twin the prevention of mother-to-child transmission (PMTCT) of HIV with that of syphilis. Thus, "PMTCT" should no longer be seen as

applicable to HIV infection alone, but to both HIV and syphilis. Such integration is a major step towards the comprehensive prevention of congenital infections.

An exciting innovation that could accelerate the PMTCT of HIV infection and syphilis is the dual rapid test for syphilis and HIV infection.⁸ In many countries supply chain management for syphilis tests is difficult. Dual rapid tests would greatly strengthen the PMTCT of syphilis because programmes for the PMTCT of HIV are better resourced and have stronger external and internal stakeholders than those for the prevention of syphilis. The community involved in the PMTCT of HIV infection is largely unaware that maternal syphilis greatly increases the risk of mother-to-child HIV transmission.⁹ Identifying and treating maternal syphilis in mothers co-infected with the HIV should further reduce the mother-to-child transmission of HIV infection.

Gomez et al's study is an important contribution to the evidence base. Evidence, however, has not been lacking in the effort to eliminate congenital syphilis, a scourge for centuries. Syphilis has affordable, safe and effective diagnostic and therapeutic tools. The missing elements have been consistently advocacy, political will and private donor investment. What will it take? Is anyone listening to the sound of silence? ■

Acknowledgements

I warmly thank Kenneth Katz for his critical review of this manuscript.

References

1. <http://www.who.int/bulletin/volumes/85/12/0711624>



HIV/AIDS Programme
Reproductive Health and Research

GUIDANCE



GLOBAL GUIDANCE ON CRITERIA AND PROCESSES FOR VALIDATION

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION (EMTCT) OF HIV AND SYPHILIS

MAY 2013

MONITORING AND EVALUATION

WHO Integrated Strategy

- **Advocacy**
 - Pro-active support for dual elimination of MTCT of HIV & syphilis
- **Programmatic**
 - Pilot projects to assess impact of integrated services on pregnant women & their partners
 - Work with *priority countries*
 - Identify in-country partners, strengthen policy support , procurement processes and laboratory supply chain
 - Increase quality & coverage of antenatal care
 - Coordinated country support for dual screening to prevent infection
 - Encourage procurement of syphilis tests through PEPFAR, Global Fund
 - Integrate training & guidelines for health workers
 - Jointly strengthen pharmacy/laboratory supply chain & QA systems
 - Support field trials of dual rapid HIV/syphilis tests

WHO Integrated Strategy

- **Surveillance & monitoring**


- Lead global process to identify criteria and process for validation/certification of elimination of MTCT of HIV and syphilis
 - Motivate to improve quality of data
 - Motivate to reach even the hardest-to-reach populations
- Include STI in agendas for HIV surveillance, M&E trainings
- Include congenital syphilis in studies of how to assess impact of elimination

- **Implementation research**

- Field testing of rapid dual HIV/syphilis tests
- How to integrate syphilis and HIV interventions within ANC?
- How to optimally measure impact of eMTCT syphilis interventions – similar methods as eMTCT HIV?

Dual Elimination Strategy: Africa, 2013

- Ensure leadership and country ownership
- Improve coverage, access and utilization of services
- Strengthen quality of MNCH services to deliver effective PMTCT interventions
- Enhance provision of linked services
- Strengthen human resource capacity, supply chain management and maintain information systems
- Improve measurement of performance and impact
- Develop and engage community systems.



Malawi Integrated monitoring and evaluation



Government of Malawi Ministry of Health

Integrated HIV Program Report January – March 2012

- HIV Testing and Counselling
- Post Exposure Prophylaxis
- HIV Exposed Child Follow-Up
- Pre-ART
- Prevention of Mother to Child Transmission / Antiretroviral Therapy
- TB / HIV
- Sexually Transmitted Infections
- Supply of HIV Program Commodities

Antenatal Care		Malawi (national)
2012 Q1 (1st month of quarter, 2nd month of quarter, 3rd month of quarter)		
New ANC registrations in reporting period		
Women with first visit in reporting period		*
New women registered	103,803	100%
ANC cohort analysis		
Total women completing ANC in the reporting period		
Total women in tracking cohort	188,251	100%
Visits per woman		
Women with 1 visit	27,454	15%
Women with 2 visits	46,409	25%
Women with 3 visits	90,732	48%
Women with 4 visits	25,202	13%
Women with 5+ visits	8,388	4%
Trimester of first visit		
Started ANC 0-12 wks	14,107	8%
Started ANC 13+ wks	155,054	82%
Pneumonia		
All pneumonias	147,945	89%
Pneumonia	3,294	2%
TTV disease		
0-1 TTV doses	71,238	42%
2+ TTV doses	58,813	38%
SP tablets		
0-9 SP tablets	128,974	71%
10+ SP tablets	49,277	29%
PAPo tablets		
0-119 PAPo tablets	188,881	100%
120+ PAPo tablets	10,800	6%
Syphilis status		
Not tested for syphilis	112,308	60%
Tested for syphilis	58,443	34%
Syphilis negative	55,875	96%
Syphilis positive	873	2%
HIV status assessment		
HIV status not ascertained	40,262	24%
HIV status ascertained	128,889	76%
Valid previous test result		
Previous negative	8,226	6%
Previous positive	3,821	3%
New test at ANC		
New negative	112,774	89%
New positive	7,338	6%
HIV status summary		
Total women HIV negative	118,806	63%
Total women HIV positive	10,809	6%

Report date: 09/07/2012

Page: 1 of 2

* Subgroups may not add to 100% due to rounding

Outline

1. WHO efforts to eliminate mother-to-child transmission of syphilis
2. UNAIDS efforts to eliminate mother-to-child transmission of HIV infection
3. Dual elimination
4. New dual rapid tests

Dual rapid diagnostics

- Simplifies training
- Streamlines procurement
- Ensures testing for both HIV and syphilis
- Improves client experience



Currently available dual rapid tests

- SD BIOLINE Duo HIV/syphilis
 - Immunochromatographic IgA, IgM, IgG assay



- Chembio DPP® HIV-Syphilis
 - Dual path platform



- MedMira Multiplo
 - Immunoreactive test membrane comprised of TP recombinant antigens (15 kDa, 17 kDa, 47 kDa) and synthetic HIV peptides to gp36, gp41, gp120 and HIV-group O



DUO HIV/syphilis principle of action

- Precoated strip with multiple antigens
 - gp41 (HIV-1)
 - gp36 (HIV-2)
 - HIV sub-O antigen
 - 17kDA TP antigen (syphilis)
- The specimen sample and sample diluent move along the membrane chromatographically to the test region (T) and form a visible line as antigen-antibody-antigen gold particle complex forms with high degree of sensitivity and specificity




Figure 1. Laboratory performance for detection of HIV antibodies using SD BIOLINE HIV/syphilis Duo test in previously characterized sera samples in 6 laboratory sites.





Figure 2. Laboratory performance for detection of *TP* antibodies using SD BIOLINE HIV/syphilis Duo test in previously characterized sera samples in 6 laboratory sites.



Summary laboratory test performance




3 rapid point-of-care dual tests

Test	Antibody	N	Sensitivity	Specificity
DPP	TP	939	95.7-100%	95.7-98.0%
DPP	HIV	939	99.1-100%	98.2-100%
Duo	TP	> 2000	98.7-100%	99.1-100%
Duo	HIV	> 2000	99.7-100%	99.2-100%
multiplo	TP	258	94.4-97.9%	100%
multiplo	HIV	Not reported	99.8%	99.7%

WHO Prequalification Progress


HIV/Syphilis Tests: Progress of the Prequalification of Diagnostics process by product

Product name	Product code(s)	Manufacturer name	Application status	Dossier request and screening	Dossier full review	On-site inspection status	Laboratory evaluation status
DPP HIV-Syphilis Assay	65-9525-0	Chembio Diagnostic Systems, Inc.	◆	◆	R		
SD BIOLINE HIV/Syphilis Duo	n/a for the moment	Standard Diagnostics, Inc.	◆	◆	R		
Multiplo Rapid TP/HIV Rapid Antibody Test	815311005091, 815311005107, and 815311005114	MedMira Inc.	◆	◆	R		

R Information requested from manufacturer	 under assessment	 stage complete	F follow-up amendments after full assessment	S scheduled; date confirmed	 application not prioritised	I determined inadequate/declined	W withdrawn by manufacturer	C closed
<p>Please note: these tables are updated regularly; while every attempt is made to provide current data, very recent info. This table is intended only as an update on progress and does not reflect a final decision on prequalification. This table should not be used to inform procurement; nation may not yet be reflected here. Last update: 5 August 2013 http://www.who.int/diagnostics_laboratory/pq_status/en/index.html</p>								

As of 5 August 2013


Sample Dual Testing Schema



Cost-Effectiveness Analysis for HIV and Syphilis Screening

Cost of Dual Rapid tests vs. Single Rapid tests for HIV and Syphilis

Hypothetical cohort of 1,000 ANC patients in South Africa



DualElimination.org

DUAL ELIMINATION OF HIV AND SYPHILIS

[HOME](#)[ABOUT DUAL ELIMINATION](#)[PUBLICATIONS](#)[TOOLS](#)[ABOUT US](#)

About Dual Elimination

Dual elimination refers to the elimination of mother-to-child transmission of HIV and syphilis, sexually transmitted infections that cause substantial global health burden. The use of dual elimination tools, such as dual rapid tests for HIV and syphilis, can significantly reduce maternal and neonatal morbidity and mortality in developing countries.

[MORE DETAILS](#)[DONATE](#)[CONTACT US](#)

Summary

- Maternal syphilis and HIV infection are common and serious infections in pregnancy causing substantial newborn morbidity and mortality
- New dual elimination strategy capitalizes on existing policy, health systems, and infrastructure to improve birth outcomes
 - Dual rapid HIV/syphilis tests are highly accurate and increasingly available
- We have the potential to transform maternal health to improve infant outcomes with new strategy of dual elimination and new tools such as dual rapid tests



Thank you



For more information:

Prof. Jeff Klausner – JDKlausner@mednet.ucla.edu

www.DualElimination.org



A generation free of HIV and syphilis

Special thanks to:

Claire Bristow, Emily Huang, Lori Newman,
Nathalie Broutet, Sarah Hawkes,
Rosanna Peeling, Mary Kamb, David Mabey,
Nicola Low, George Schmid, Brad Stoner,
Patty Garcia and many others

Happy Holidays

